nodes	percent_of_prediction	percent_of_DWPC	metapath
Lidocaine—osteoarthritis—Prednisone—systemic scleroderma	0.55	1	CpDpCtD
Lidocaine—CYP2C8—Mometasone—systemic scleroderma	0.0574	0.189	CbGbCtD
Lidocaine—CYP1A2—Pentoxifylline—systemic scleroderma	0.03	0.0989	CbGbCtD
Lidocaine—CYP1A2—Leflunomide—systemic scleroderma	0.0287	0.0943	CbGbCtD
Lidocaine—ABCB1—Lisinopril—systemic scleroderma	0.0263	0.0865	CbGbCtD
Lidocaine—CYP2C9—Leflunomide—systemic scleroderma	0.0258	0.085	CbGbCtD
Lidocaine—CYP3A5—Mycophenolate mofetil—systemic scleroderma	0.0238	0.0783	CbGbCtD
Lidocaine—CYP2C8—Mycophenolate mofetil—systemic scleroderma	0.0229	0.0753	CbGbCtD
Lidocaine—ABCB1—Captopril—systemic scleroderma	0.0197	0.0647	CbGbCtD
Lidocaine—CYP2D6—Captopril—systemic scleroderma	0.0185	0.061	CbGbCtD
Lidocaine—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0155	0.051	CbGbCtD
Lidocaine—ABCB1—Prednisone—systemic scleroderma	0.0124	0.0407	CbGbCtD
Lidocaine—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.00927	0.0305	CbGbCtD
Lidocaine—CYP3A4—Prednisone—systemic scleroderma	0.00741	0.0244	CbGbCtD
Lidocaine—ABCB1—Methotrexate—systemic scleroderma	0.00621	0.0204	CbGbCtD
Lidocaine—CYP2C9—cardial valve—systemic scleroderma	0.00316	0.37	CbGeAlD
Lidocaine—CYP2C18—digestive system—systemic scleroderma	0.000415	0.0487	CbGeAlD
Lidocaine—EGFR—lung—systemic scleroderma	0.000402	0.047	CbGeAlD
Lidocaine—SCN9A—tendon—systemic scleroderma	0.000377	0.0441	CbGeAlD
Lidocaine—SCN4A—tendon—systemic scleroderma	0.000336	0.0394	CbGeAlD
Lidocaine—SCN9A—lung—systemic scleroderma	0.000331	0.0387	CbGeAlD
Lidocaine—SCN5A—digestive system—systemic scleroderma	0.000274	0.0321	CbGeAlD
Lidocaine—SCN3A—tendon—systemic scleroderma	0.000261	0.0306	CbGeAlD
Lidocaine—SCN10A—lung—systemic scleroderma	0.000252	0.0295	CbGeAlD
Lidocaine—Vision blurred—Leflunomide—systemic scleroderma	0.000243	0.00177	CcSEcCtD
Lidocaine—Depressed level of consciousness—Methotrexate—systemic scleroderma	0.000243	0.00177	CcSEcCtD
Lidocaine—Stomatitis—Mycophenolate mofetil—systemic scleroderma	0.000242	0.00176	CcSEcCtD
Lidocaine—Asthenia—Pentoxifylline—systemic scleroderma	0.000242	0.00176	CcSEcCtD
Lidocaine—Tension—Mycophenolic acid—systemic scleroderma	0.000241	0.00176	CcSEcCtD
Lidocaine—Skin exfoliation—Methotrexate—systemic scleroderma	0.00024	0.00175	CcSEcCtD
Lidocaine—Nervousness—Mycophenolic acid—systemic scleroderma	0.000239	0.00174	CcSEcCtD
Lidocaine—Hypotension—Captopril—systemic scleroderma	0.000239	0.00174	CcSEcCtD
Lidocaine—Back pain—Mycophenolic acid—systemic scleroderma	0.000238	0.00173	CcSEcCtD
Lidocaine—Tinnitus—Lisinopril—systemic scleroderma	0.000237	0.00173	CcSEcCtD
Lidocaine—Flushing—Lisinopril—systemic scleroderma	0.000236	0.00172	CcSEcCtD
Lidocaine—Angioedema—Leflunomide—systemic scleroderma	0.000236	0.00172	CcSEcCtD
Lidocaine—Vision blurred—Mycophenolic acid—systemic scleroderma	0.000232	0.00169	CcSEcCtD
Lidocaine—Angiopathy—Lisinopril—systemic scleroderma	0.000231	0.00168	CcSEcCtD
Lidocaine—Tremor—Mycophenolic acid—systemic scleroderma	0.00023	0.00168	CcSEcCtD
Lidocaine—Coma—Methotrexate—systemic scleroderma	0.00023	0.00168	CcSEcCtD
Lidocaine—SCN3A—lung—systemic scleroderma	0.000229	0.0269	CbGeAlD
Lidocaine—CYP2A6—lung—systemic scleroderma	0.000229	0.0269	CbGeAlD
Lidocaine—Paraesthesia—Captopril—systemic scleroderma	0.000229	0.00167	CcSEcCtD
Lidocaine—Chills—Lisinopril—systemic scleroderma	0.000228	0.00166	CcSEcCtD
Lidocaine—Dyspnoea—Captopril—systemic scleroderma	0.000228	0.00166	CcSEcCtD
Lidocaine—Bradycardia—Mycophenolate mofetil—systemic scleroderma	0.000227	0.00165	CcSEcCtD
Lidocaine—Somnolence—Captopril—systemic scleroderma	0.000227	0.00165	CcSEcCtD
Lidocaine—Agitation—Mycophenolic acid—systemic scleroderma	0.000226	0.00165	CcSEcCtD
Lidocaine—Haemoglobin—Mycophenolate mofetil—systemic scleroderma	0.000224	0.00163	CcSEcCtD
Lidocaine—Rhinitis—Mycophenolate mofetil—systemic scleroderma	0.000224	0.00163	CcSEcCtD
Lidocaine—Haemorrhage—Mycophenolate mofetil—systemic scleroderma	0.000223	0.00163	CcSEcCtD
Lidocaine—Dizziness—Pentoxifylline—systemic scleroderma	0.000223	0.00162	CcSEcCtD
Lidocaine—Hypertension—Leflunomide—systemic scleroderma	0.000223	0.00162	CcSEcCtD
Lidocaine—Hypoaesthesia—Mycophenolate mofetil—systemic scleroderma	0.000222	0.00162	CcSEcCtD
Lidocaine—Erythema—Lisinopril—systemic scleroderma	0.000222	0.00161	CcSEcCtD
Lidocaine—Chest pain—Leflunomide—systemic scleroderma	0.00022	0.0016	CcSEcCtD
Lidocaine—Anxiety—Leflunomide—systemic scleroderma	0.000219	0.00159	CcSEcCtD
Lidocaine—Osteoarthritis—Prednisone—systemic scleroderma	0.000219	0.00159	CcSEcCtD
Lidocaine—Tension—Lisinopril—systemic scleroderma	0.000217	0.00158	CcSEcCtD
Lidocaine—Dysgeusia—Lisinopril—systemic scleroderma	0.000217	0.00158	CcSEcCtD
Lidocaine—Loss of consciousness—Mycophenolic acid—systemic scleroderma	0.000216	0.00158	CcSEcCtD
Lidocaine—Nervousness—Lisinopril—systemic scleroderma	0.000215	0.00157	CcSEcCtD
Lidocaine—Visual impairment—Mycophenolate mofetil—systemic scleroderma	0.000215	0.00157	CcSEcCtD
Lidocaine—Back pain—Lisinopril—systemic scleroderma	0.000214	0.00156	CcSEcCtD
Lidocaine—Vomiting—Pentoxifylline—systemic scleroderma	0.000214	0.00156	CcSEcCtD
Lidocaine—Psychotic disorder—Prednisone—systemic scleroderma	0.000213	0.00156	CcSEcCtD
Lidocaine—Convulsion—Mycophenolic acid—systemic scleroderma	0.000213	0.00155	CcSEcCtD
Lidocaine—Rash—Pentoxifylline—systemic scleroderma	0.000212	0.00155	CcSEcCtD
Lidocaine—Hypertension—Mycophenolic acid—systemic scleroderma	0.000212	0.00155	CcSEcCtD
Lidocaine—Dermatitis—Pentoxifylline—systemic scleroderma	0.000212	0.00155	CcSEcCtD
Lidocaine—Headache—Pentoxifylline—systemic scleroderma	0.000211	0.00154	CcSEcCtD
Lidocaine—Anaphylactic shock—Leflunomide—systemic scleroderma	0.00021	0.00153	CcSEcCtD
Lidocaine—Feeling abnormal—Captopril—systemic scleroderma	0.00021	0.00153	CcSEcCtD
Lidocaine—Chest pain—Mycophenolic acid—systemic scleroderma	0.000209	0.00153	CcSEcCtD
Lidocaine—Vision blurred—Lisinopril—systemic scleroderma	0.000209	0.00152	CcSEcCtD
Lidocaine—Anxiety—Mycophenolic acid—systemic scleroderma	0.000209	0.00152	CcSEcCtD
Lidocaine—Asthenia—Mometasone—systemic scleroderma	0.000209	0.00152	CcSEcCtD
Lidocaine—Eye disorder—Mycophenolate mofetil—systemic scleroderma	0.000208	0.00152	CcSEcCtD
Lidocaine—Hypotension—Azathioprine—systemic scleroderma	0.000208	0.00152	CcSEcCtD
Lidocaine—Tinnitus—Mycophenolate mofetil—systemic scleroderma	0.000208	0.00152	CcSEcCtD
Lidocaine—Cardiac arrest—Prednisone—systemic scleroderma	0.000208	0.00151	CcSEcCtD
Lidocaine—Tremor—Lisinopril—systemic scleroderma	0.000208	0.00151	CcSEcCtD
Lidocaine—Cardiac disorder—Mycophenolate mofetil—systemic scleroderma	0.000207	0.00151	CcSEcCtD
Lidocaine—Nervous system disorder—Leflunomide—systemic scleroderma	0.000206	0.0015	CcSEcCtD
Lidocaine—Hyperhidrosis—Leflunomide—systemic scleroderma	0.000203	0.00148	CcSEcCtD
Lidocaine—Angioedema—Lisinopril—systemic scleroderma	0.000202	0.00148	CcSEcCtD
Lidocaine—Confusional state—Mycophenolic acid—systemic scleroderma	0.000202	0.00148	CcSEcCtD
Lidocaine—Angiopathy—Mycophenolate mofetil—systemic scleroderma	0.000202	0.00147	CcSEcCtD
Lidocaine—Oedema—Mycophenolic acid—systemic scleroderma	0.000201	0.00146	CcSEcCtD
Lidocaine—Nausea—Pentoxifylline—systemic scleroderma	0.0002	0.00146	CcSEcCtD
Lidocaine—Chills—Mycophenolate mofetil—systemic scleroderma	0.0002	0.00146	CcSEcCtD
Lidocaine—ABCB1—blood vessel—systemic scleroderma	0.0002	0.0234	CbGeAlD
Lidocaine—SLC22A5—skin of body—systemic scleroderma	0.000199	0.0233	CbGeAlD
Lidocaine—Shock—Mycophenolic acid—systemic scleroderma	0.000198	0.00144	CcSEcCtD
Lidocaine—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.000197	0.00143	CcSEcCtD
Lidocaine—Hypotension—Leflunomide—systemic scleroderma	0.000197	0.00143	CcSEcCtD
Lidocaine—Loss of consciousness—Lisinopril—systemic scleroderma	0.000195	0.00142	CcSEcCtD
Lidocaine—Hyperhidrosis—Mycophenolic acid—systemic scleroderma	0.000194	0.00141	CcSEcCtD
Lidocaine—Visual disturbance—Methotrexate—systemic scleroderma	0.000193	0.0014	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.000192	0.0014	CcSEcCtD
Lidocaine—Tension—Mycophenolate mofetil—systemic scleroderma	0.000191	0.00139	CcSEcCtD
Lidocaine—Dysgeusia—Mycophenolate mofetil—systemic scleroderma	0.00019	0.00139	CcSEcCtD
Lidocaine—Paraesthesia—Leflunomide—systemic scleroderma	0.000189	0.00138	CcSEcCtD
Lidocaine—Anaphylactoid reaction—Methotrexate—systemic scleroderma	0.000189	0.00137	CcSEcCtD
Lidocaine—Chest pain—Lisinopril—systemic scleroderma	0.000189	0.00137	CcSEcCtD
Lidocaine—Nervousness—Mycophenolate mofetil—systemic scleroderma	0.000189	0.00137	CcSEcCtD
Lidocaine—Anxiety—Lisinopril—systemic scleroderma	0.000188	0.00137	CcSEcCtD
Lidocaine—Back pain—Mycophenolate mofetil—systemic scleroderma	0.000188	0.00137	CcSEcCtD
Lidocaine—Dyspnoea—Leflunomide—systemic scleroderma	0.000188	0.00137	CcSEcCtD
Lidocaine—Hypotension—Mycophenolic acid—systemic scleroderma	0.000188	0.00137	CcSEcCtD
Lidocaine—Vomiting—Mometasone—systemic scleroderma	0.000185	0.00135	CcSEcCtD
Lidocaine—Sweating increased—Prednisone—systemic scleroderma	0.000184	0.00134	CcSEcCtD
Lidocaine—Feeling abnormal—Azathioprine—systemic scleroderma	0.000184	0.00134	CcSEcCtD
Lidocaine—Rash—Mometasone—systemic scleroderma	0.000183	0.00134	CcSEcCtD
Lidocaine—Asthenia—Captopril—systemic scleroderma	0.000183	0.00133	CcSEcCtD
Lidocaine—Dermatitis—Mometasone—systemic scleroderma	0.000183	0.00133	CcSEcCtD
Lidocaine—Osteoarthritis—Methotrexate—systemic scleroderma	0.000183	0.00133	CcSEcCtD
Lidocaine—Confusional state—Lisinopril—systemic scleroderma	0.000182	0.00133	CcSEcCtD
Lidocaine—Headache—Mometasone—systemic scleroderma	0.000182	0.00133	CcSEcCtD
Lidocaine—Tremor—Mycophenolate mofetil—systemic scleroderma	0.000182	0.00133	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000182	0.00132	CcSEcCtD
Lidocaine—Oedema—Lisinopril—systemic scleroderma	0.000181	0.00132	CcSEcCtD
Lidocaine—Anaphylactic shock—Lisinopril—systemic scleroderma	0.000181	0.00132	CcSEcCtD
Lidocaine—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.00018	0.00131	CcSEcCtD
Lidocaine—Pain—Leflunomide—systemic scleroderma	0.00018	0.00131	CcSEcCtD
Lidocaine—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000179	0.0013	CcSEcCtD
Lidocaine—Somnolence—Mycophenolic acid—systemic scleroderma	0.000178	0.0013	CcSEcCtD
Lidocaine—Agitation—Mycophenolate mofetil—systemic scleroderma	0.000178	0.0013	CcSEcCtD
Lidocaine—Shock—Lisinopril—systemic scleroderma	0.000178	0.0013	CcSEcCtD
Lidocaine—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.000177	0.00129	CcSEcCtD
Lidocaine—Hyperhidrosis—Lisinopril—systemic scleroderma	0.000175	0.00127	CcSEcCtD
Lidocaine—Feeling abnormal—Leflunomide—systemic scleroderma	0.000173	0.00126	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000173	0.00126	CcSEcCtD
Lidocaine—CYP2B6—skin of body—systemic scleroderma	0.000173	0.0202	CbGeAlD
Lidocaine—Nausea—Mometasone—systemic scleroderma	0.000173	0.00126	CcSEcCtD
Lidocaine—Pain—Mycophenolic acid—systemic scleroderma	0.000172	0.00125	CcSEcCtD
Lidocaine—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000171	0.00124	CcSEcCtD
Lidocaine—Hypotension—Lisinopril—systemic scleroderma	0.000169	0.00123	CcSEcCtD
Lidocaine—Dizziness—Captopril—systemic scleroderma	0.000169	0.00123	CcSEcCtD
Lidocaine—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.000168	0.00123	CcSEcCtD
Lidocaine—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000168	0.00122	CcSEcCtD
Lidocaine—Urticaria—Leflunomide—systemic scleroderma	0.000167	0.00122	CcSEcCtD
Lidocaine—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000165	0.00121	CcSEcCtD
Lidocaine—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000165	0.0012	CcSEcCtD
Lidocaine—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000165	0.0012	CcSEcCtD
Lidocaine—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000165	0.0012	CcSEcCtD
Lidocaine—Hypersensitivity—Azathioprine—systemic scleroderma	0.000164	0.0012	CcSEcCtD
Lidocaine—Paraesthesia—Lisinopril—systemic scleroderma	0.000162	0.00118	CcSEcCtD
Lidocaine—Vomiting—Captopril—systemic scleroderma	0.000162	0.00118	CcSEcCtD
Lidocaine—Dyspnoea—Lisinopril—systemic scleroderma	0.000161	0.00117	CcSEcCtD
Lidocaine—Rash—Captopril—systemic scleroderma	0.000161	0.00117	CcSEcCtD
Lidocaine—Dermatitis—Captopril—systemic scleroderma	0.000161	0.00117	CcSEcCtD
Lidocaine—Somnolence—Lisinopril—systemic scleroderma	0.000161	0.00117	CcSEcCtD
Lidocaine—Headache—Captopril—systemic scleroderma	0.00016	0.00117	CcSEcCtD
Lidocaine—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.00016	0.00116	CcSEcCtD
Lidocaine—SLC22A5—digestive system—systemic scleroderma	0.000159	0.0186	CbGeAlD
Lidocaine—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000158	0.00115	CcSEcCtD
Lidocaine—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000158	0.00115	CcSEcCtD
Lidocaine—Asthma—Methotrexate—systemic scleroderma	0.000158	0.00115	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000156	0.00114	CcSEcCtD
Lidocaine—Shock—Mycophenolate mofetil—systemic scleroderma	0.000156	0.00114	CcSEcCtD
Lidocaine—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000155	0.00113	CcSEcCtD
Lidocaine—Hypersensitivity—Leflunomide—systemic scleroderma	0.000155	0.00113	CcSEcCtD
Lidocaine—Pain—Lisinopril—systemic scleroderma	0.000155	0.00113	CcSEcCtD
Lidocaine—Bradycardia—Prednisone—systemic scleroderma	0.000154	0.00112	CcSEcCtD
Lidocaine—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000153	0.00112	CcSEcCtD
Lidocaine—Haemoglobin—Prednisone—systemic scleroderma	0.000152	0.00111	CcSEcCtD
Lidocaine—Nausea—Captopril—systemic scleroderma	0.000152	0.00111	CcSEcCtD
Lidocaine—SLC22A5—tendon—systemic scleroderma	0.000152	0.0177	CbGeAlD
Lidocaine—Haemorrhage—Prednisone—systemic scleroderma	0.000151	0.0011	CcSEcCtD
Lidocaine—Asthenia—Leflunomide—systemic scleroderma	0.000151	0.0011	CcSEcCtD
Lidocaine—Feeling abnormal—Lisinopril—systemic scleroderma	0.000149	0.00109	CcSEcCtD
Lidocaine—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000148	0.00108	CcSEcCtD
Lidocaine—Dizziness—Azathioprine—systemic scleroderma	0.000147	0.00107	CcSEcCtD
Lidocaine—CYP1A2—digestive system—systemic scleroderma	0.000144	0.0169	CbGeAlD
Lidocaine—Asthenia—Mycophenolic acid—systemic scleroderma	0.000144	0.00105	CcSEcCtD
Lidocaine—Urticaria—Lisinopril—systemic scleroderma	0.000144	0.00105	CcSEcCtD
Lidocaine—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000142	0.00104	CcSEcCtD
Lidocaine—Vomiting—Azathioprine—systemic scleroderma	0.000142	0.00103	CcSEcCtD
Lidocaine—Eye disorder—Prednisone—systemic scleroderma	0.000141	0.00103	CcSEcCtD
Lidocaine—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000141	0.00103	CcSEcCtD
Lidocaine—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000141	0.00103	CcSEcCtD
Lidocaine—Drowsiness—Methotrexate—systemic scleroderma	0.000141	0.00103	CcSEcCtD
Lidocaine—Rash—Azathioprine—systemic scleroderma	0.000141	0.00102	CcSEcCtD
Lidocaine—Dermatitis—Azathioprine—systemic scleroderma	0.00014	0.00102	CcSEcCtD
Lidocaine—Flushing—Prednisone—systemic scleroderma	0.00014	0.00102	CcSEcCtD
Lidocaine—Headache—Azathioprine—systemic scleroderma	0.00014	0.00102	CcSEcCtD
Lidocaine—Dizziness—Leflunomide—systemic scleroderma	0.000139	0.00101	CcSEcCtD
Lidocaine—CYP3A5—digestive system—systemic scleroderma	0.000139	0.0163	CbGeAlD
Lidocaine—CYP2B6—digestive system—systemic scleroderma	0.000138	0.0162	CbGeAlD
Lidocaine—Stomatitis—Methotrexate—systemic scleroderma	0.000137	0.001	CcSEcCtD
Lidocaine—Angiopathy—Prednisone—systemic scleroderma	0.000137	0.000999	CcSEcCtD
Lidocaine—CYP2C9—digestive system—systemic scleroderma	0.000137	0.016	CbGeAlD
Lidocaine—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000137	0.000997	CcSEcCtD
Lidocaine—Immune system disorder—Prednisone—systemic scleroderma	0.000137	0.000995	CcSEcCtD
Lidocaine—Pain—Mycophenolate mofetil—systemic scleroderma	0.000135	0.000987	CcSEcCtD
Lidocaine—Vomiting—Leflunomide—systemic scleroderma	0.000134	0.000975	CcSEcCtD
Lidocaine—Hypersensitivity—Lisinopril—systemic scleroderma	0.000133	0.000971	CcSEcCtD
Lidocaine—SLC22A5—lung—systemic scleroderma	0.000133	0.0156	CbGeAlD
Lidocaine—Dizziness—Mycophenolic acid—systemic scleroderma	0.000133	0.000967	CcSEcCtD
Lidocaine—Rash—Leflunomide—systemic scleroderma	0.000133	0.000967	CcSEcCtD
Lidocaine—Dermatitis—Leflunomide—systemic scleroderma	0.000133	0.000966	CcSEcCtD
Lidocaine—Nausea—Azathioprine—systemic scleroderma	0.000132	0.000965	CcSEcCtD
Lidocaine—Headache—Leflunomide—systemic scleroderma	0.000132	0.000961	CcSEcCtD
Lidocaine—Erythema—Prednisone—systemic scleroderma	0.000132	0.000959	CcSEcCtD
Lidocaine—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000131	0.000951	CcSEcCtD
Lidocaine—Asthenia—Lisinopril—systemic scleroderma	0.00013	0.000945	CcSEcCtD
Lidocaine—Vomiting—Mycophenolic acid—systemic scleroderma	0.000128	0.00093	CcSEcCtD
Lidocaine—Haemoglobin—Methotrexate—systemic scleroderma	0.000127	0.000925	CcSEcCtD
Lidocaine—Rash—Mycophenolic acid—systemic scleroderma	0.000127	0.000922	CcSEcCtD
Lidocaine—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000126	0.000922	CcSEcCtD
Lidocaine—Haemorrhage—Methotrexate—systemic scleroderma	0.000126	0.000921	CcSEcCtD
Lidocaine—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000126	0.000917	CcSEcCtD
Lidocaine—Headache—Mycophenolic acid—systemic scleroderma	0.000126	0.000916	CcSEcCtD
Lidocaine—Nausea—Leflunomide—systemic scleroderma	0.000125	0.000911	CcSEcCtD
Lidocaine—Vision blurred—Prednisone—systemic scleroderma	0.000124	0.000904	CcSEcCtD
Lidocaine—Visual impairment—Methotrexate—systemic scleroderma	0.000122	0.000887	CcSEcCtD
Lidocaine—Agitation—Prednisone—systemic scleroderma	0.000121	0.000881	CcSEcCtD
Lidocaine—CYP1A2—lung—systemic scleroderma	0.00012	0.0141	CbGeAlD
Lidocaine—Angioedema—Prednisone—systemic scleroderma	0.00012	0.000876	CcSEcCtD
Lidocaine—Dizziness—Lisinopril—systemic scleroderma	0.00012	0.000871	CcSEcCtD
Lidocaine—Nausea—Mycophenolic acid—systemic scleroderma	0.000119	0.000869	CcSEcCtD
Lidocaine—Eye disorder—Methotrexate—systemic scleroderma	0.000118	0.00086	CcSEcCtD
Lidocaine—Tinnitus—Methotrexate—systemic scleroderma	0.000118	0.000858	CcSEcCtD
Lidocaine—Cardiac disorder—Methotrexate—systemic scleroderma	0.000117	0.000854	CcSEcCtD
Lidocaine—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000117	0.000851	CcSEcCtD
Lidocaine—CYP3A5—lung—systemic scleroderma	0.000116	0.0136	CbGeAlD
Lidocaine—Loss of consciousness—Prednisone—systemic scleroderma	0.000116	0.000843	CcSEcCtD
Lidocaine—CYP2B6—lung—systemic scleroderma	0.000115	0.0135	CbGeAlD
Lidocaine—Vomiting—Lisinopril—systemic scleroderma	0.000115	0.000838	CcSEcCtD
Lidocaine—Angiopathy—Methotrexate—systemic scleroderma	0.000115	0.000835	CcSEcCtD
Lidocaine—Immune system disorder—Methotrexate—systemic scleroderma	0.000114	0.000832	CcSEcCtD
Lidocaine—Rash—Lisinopril—systemic scleroderma	0.000114	0.000831	CcSEcCtD
Lidocaine—Convulsion—Prednisone—systemic scleroderma	0.000114	0.000831	CcSEcCtD
Lidocaine—Dermatitis—Lisinopril—systemic scleroderma	0.000114	0.00083	CcSEcCtD
Lidocaine—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000114	0.000828	CcSEcCtD
Lidocaine—Hypertension—Prednisone—systemic scleroderma	0.000114	0.000828	CcSEcCtD
Lidocaine—Chills—Methotrexate—systemic scleroderma	0.000113	0.000826	CcSEcCtD
Lidocaine—Headache—Lisinopril—systemic scleroderma	0.000113	0.000825	CcSEcCtD
Lidocaine—Anxiety—Prednisone—systemic scleroderma	0.000112	0.000814	CcSEcCtD
Lidocaine—Erythema—Methotrexate—systemic scleroderma	0.00011	0.000801	CcSEcCtD
Lidocaine—Dysgeusia—Methotrexate—systemic scleroderma	0.000108	0.000785	CcSEcCtD
Lidocaine—Nausea—Lisinopril—systemic scleroderma	0.000107	0.000783	CcSEcCtD
Lidocaine—Oedema—Prednisone—systemic scleroderma	0.000107	0.000783	CcSEcCtD
Lidocaine—Anaphylactic shock—Prednisone—systemic scleroderma	0.000107	0.000783	CcSEcCtD
Lidocaine—Back pain—Methotrexate—systemic scleroderma	0.000106	0.000775	CcSEcCtD
Lidocaine—Shock—Prednisone—systemic scleroderma	0.000106	0.00077	CcSEcCtD
Lidocaine—Nervous system disorder—Prednisone—systemic scleroderma	0.000105	0.000767	CcSEcCtD
Lidocaine—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000105	0.000763	CcSEcCtD
Lidocaine—CYP3A4—digestive system—systemic scleroderma	0.000104	0.0122	CbGeAlD
Lidocaine—Hyperhidrosis—Prednisone—systemic scleroderma	0.000104	0.000757	CcSEcCtD
Lidocaine—Vision blurred—Methotrexate—systemic scleroderma	0.000104	0.000755	CcSEcCtD
Lidocaine—CYP2D6—digestive system—systemic scleroderma	0.000103	0.012	CbGeAlD
Lidocaine—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000101	0.000734	CcSEcCtD
Lidocaine—Rash—Mycophenolate mofetil—systemic scleroderma	9.99e-05	0.000728	CcSEcCtD
Lidocaine—Dermatitis—Mycophenolate mofetil—systemic scleroderma	9.98e-05	0.000727	CcSEcCtD
Lidocaine—Headache—Mycophenolate mofetil—systemic scleroderma	9.93e-05	0.000723	CcSEcCtD
Lidocaine—Paraesthesia—Prednisone—systemic scleroderma	9.64e-05	0.000703	CcSEcCtD
Lidocaine—Convulsion—Methotrexate—systemic scleroderma	9.53e-05	0.000694	CcSEcCtD
Lidocaine—Nausea—Mycophenolate mofetil—systemic scleroderma	9.41e-05	0.000686	CcSEcCtD
Lidocaine—Chest pain—Methotrexate—systemic scleroderma	9.36e-05	0.000682	CcSEcCtD
Lidocaine—Confusional state—Methotrexate—systemic scleroderma	9.05e-05	0.000659	CcSEcCtD
Lidocaine—Anaphylactic shock—Methotrexate—systemic scleroderma	8.98e-05	0.000654	CcSEcCtD
Lidocaine—Feeling abnormal—Prednisone—systemic scleroderma	8.85e-05	0.000645	CcSEcCtD
Lidocaine—Nervous system disorder—Methotrexate—systemic scleroderma	8.8e-05	0.000641	CcSEcCtD
Lidocaine—Hyperhidrosis—Methotrexate—systemic scleroderma	8.68e-05	0.000632	CcSEcCtD
Lidocaine—Urticaria—Prednisone—systemic scleroderma	8.53e-05	0.000622	CcSEcCtD
Lidocaine—Hypotension—Methotrexate—systemic scleroderma	8.39e-05	0.000611	CcSEcCtD
Lidocaine—Paraesthesia—Methotrexate—systemic scleroderma	8.06e-05	0.000587	CcSEcCtD
Lidocaine—Dyspnoea—Methotrexate—systemic scleroderma	8e-05	0.000583	CcSEcCtD
Lidocaine—Somnolence—Methotrexate—systemic scleroderma	7.98e-05	0.000581	CcSEcCtD
Lidocaine—Hypersensitivity—Prednisone—systemic scleroderma	7.91e-05	0.000577	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Methotrexate—systemic scleroderma	7.75e-05	0.000565	CcSEcCtD
Lidocaine—Asthenia—Prednisone—systemic scleroderma	7.71e-05	0.000561	CcSEcCtD
Lidocaine—Pain—Methotrexate—systemic scleroderma	7.68e-05	0.000559	CcSEcCtD
Lidocaine—Feeling abnormal—Methotrexate—systemic scleroderma	7.4e-05	0.000539	CcSEcCtD
Lidocaine—ABCB1—digestive system—systemic scleroderma	7.39e-05	0.00866	CbGeAlD
Lidocaine—Urticaria—Methotrexate—systemic scleroderma	7.13e-05	0.00052	CcSEcCtD
Lidocaine—Dizziness—Prednisone—systemic scleroderma	7.1e-05	0.000518	CcSEcCtD
Lidocaine—Vomiting—Prednisone—systemic scleroderma	6.83e-05	0.000498	CcSEcCtD
Lidocaine—Rash—Prednisone—systemic scleroderma	6.77e-05	0.000493	CcSEcCtD
Lidocaine—Dermatitis—Prednisone—systemic scleroderma	6.77e-05	0.000493	CcSEcCtD
Lidocaine—Headache—Prednisone—systemic scleroderma	6.73e-05	0.00049	CcSEcCtD
Lidocaine—Hypersensitivity—Methotrexate—systemic scleroderma	6.61e-05	0.000482	CcSEcCtD
Lidocaine—Asthenia—Methotrexate—systemic scleroderma	6.44e-05	0.000469	CcSEcCtD
Lidocaine—Nausea—Prednisone—systemic scleroderma	6.38e-05	0.000465	CcSEcCtD
Lidocaine—ABCB1—lung—systemic scleroderma	6.17e-05	0.00723	CbGeAlD
Lidocaine—Dizziness—Methotrexate—systemic scleroderma	5.94e-05	0.000432	CcSEcCtD
Lidocaine—Vomiting—Methotrexate—systemic scleroderma	5.71e-05	0.000416	CcSEcCtD
Lidocaine—Rash—Methotrexate—systemic scleroderma	5.66e-05	0.000412	CcSEcCtD
Lidocaine—Dermatitis—Methotrexate—systemic scleroderma	5.65e-05	0.000412	CcSEcCtD
Lidocaine—Headache—Methotrexate—systemic scleroderma	5.62e-05	0.00041	CcSEcCtD
Lidocaine—Nausea—Methotrexate—systemic scleroderma	5.33e-05	0.000388	CcSEcCtD
